Hospira Assumes Responsibility For Recent Abbott Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets